These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33932429)

  • 1. Apparent treatment resistant hypertension and the risk of recurrent cardiovascular events and mortality in patients with established vascular disease.
    Groenland EH; Bots ML; Asselbergs FW; de Borst GJ; Kappelle LJ; Visseren FLJ; Spiering W;
    Int J Cardiol; 2021 Jul; 334():135-141. PubMed ID: 33932429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of cardiovascular and renal risk among patients with apparent treatment-resistant hypertension in the United States using machine learning methods.
    Bakris G; Lin PP; Xu C; Chen C; Ashton V; Singhal M
    J Clin Hypertens (Greenwich); 2024 May; 26(5):500-513. PubMed ID: 38523465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Muntner P; Davis BR; Cushman WC; Bangalore S; Calhoun DA; Pressel SL; Black HR; Kostis JB; Probstfield JL; Whelton PK; Rahman M;
    Hypertension; 2014 Nov; 64(5):1012-21. PubMed ID: 25259745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: a report from the NHLBI-sponsored WISE Study.
    Smith SM; Huo T; Delia Johnson B; Bittner V; Kelsey SF; Vido Thompson D; Noel Bairey Merz C; Pepine CJ; Cooper-Dehoff RM
    J Am Heart Assoc; 2014 Feb; 3(1):e000660. PubMed ID: 24584740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of Apparent Therapy-Resistant Hypertension and Its Effect on Outcome in Patients With Chronic Kidney Disease.
    de Beus E; Bots ML; van Zuilen AD; Wetzels JF; Blankestijn PJ;
    Hypertension; 2015 Nov; 66(5):998-1005. PubMed ID: 26351024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistant hypertension and cardiovascular disease mortality in the US: results from the National Health and Nutrition Examination Survey (NHANES).
    Kaczmarski KR; Sozio SM; Chen J; Sang Y; Shafi T
    BMC Nephrol; 2019 Apr; 20(1):138. PubMed ID: 31023262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and clinical characteristics of apparent therapy-resistant hypertension in patients with cardiovascular disease: a cross-sectional cohort study in secondary care.
    de Beus E; van der Sande NGC; Bots ML; Spiering W; Voskuil M; Visseren FLJ; Blankestijn PJ
    BMJ Open; 2017 Sep; 7(9):e016692. PubMed ID: 28882918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study.
    Thomas G; Xie D; Chen HY; Anderson AH; Appel LJ; Bodana S; Brecklin CS; Drawz P; Flack JM; Miller ER; Steigerwalt SP; Townsend RR; Weir MR; Wright JT; Rahman M;
    Hypertension; 2016 Feb; 67(2):387-96. PubMed ID: 26711738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus.
    Bakris G; Chen C; Campbell AK; Ashton V; Haskell L; Singhal M
    J Clin Hypertens (Greenwich); 2023 Aug; 25(8):737-747. PubMed ID: 37461262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apparent Treatment-Resistant Hypertension in the First Year Associated With Cardiovascular Mortality in Peritoneal Dialysis Patients.
    Zhu Q; Huo Z; Zeng F; Gong N; Ye P; Pan J; Kong Y; Dou X; Wang D; Huang S; Yang C; Liu D; Zhang G; Ai J
    Am J Hypertens; 2024 Jun; 37(7):514-522. PubMed ID: 38252960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apparent Treatment-Resistant Hypertension and Cardiovascular Risk in Hemodialysis Patients: Ten-Year Outcomes of the Q-Cohort Study.
    Tanaka S; Ninomiya T; Hiyamuta H; Taniguchi M; Tokumoto M; Masutani K; Ooboshi H; Nakano T; Tsuruya K; Kitazono T
    Sci Rep; 2019 Jan; 9(1):1043. PubMed ID: 30705378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Health and Transition From Controlled Blood Pressure to Apparent Treatment Resistant Hypertension: The Jackson Heart Study and the REGARDS Study.
    Akinyelure OP; Sakhuja S; Colvin CL; Clark D; Jaeger BC; Hardy ST; Howard G; Cohen LP; Irvin MR; Tanner R; Carey RM; Muntner P
    Hypertension; 2020 Dec; 76(6):1953-1961. PubMed ID: 33131312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation and Apparent Treatment-Resistant Hypertension in Patients With Chronic Kidney Disease.
    Chen J; Bundy JD; Hamm LL; Hsu CY; Lash J; Miller ER; Thomas G; Cohen DL; Weir MR; Raj DS; Chen HY; Xie D; Rao P; Wright JT; Rahman M; He J
    Hypertension; 2019 Apr; 73(4):785-793. PubMed ID: 30776971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apparent resistant hypertension and the risk of vascular events and mortality in patients with manifest vascular disease.
    van der Sande NGC; de Beus E; Bots ML; Voskuil M; Blankestijn PJ; Visseren F; Spiering W;
    J Hypertens; 2018 Jan; 36(1):143-150. PubMed ID: 28763342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apparent Treatment Resistant Hypertension Among Stroke Survivors in Ghana.
    Sarfo FS; Ovbiagele B
    J Stroke Cerebrovasc Dis; 2020 Dec; 29(12):105401. PubMed ID: 33096498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality.
    Irvin MR; Booth JN; Shimbo D; Lackland DT; Oparil S; Howard G; Safford MM; Muntner P; Calhoun DA
    J Am Soc Hypertens; 2014 Jun; 8(6):405-13. PubMed ID: 24952653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Impact of Blood Pressure Control in Patients With Apparent Treatment-Resistant or Difficult-to-Control Hypertension and Stages 3 and 4 Chronic Kidney Disease.
    Bakris G; Chen C; Campbell AK; Ashton V; Haskell L; Singhal M
    Am J Hypertens; 2024 May; 37(6):438-446. PubMed ID: 38436491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Resistant hypertension and the risk of major adverse cardiac and cerebrovascular events in outpatients].
    Xia JH; Wang XY; Kang YY; Huang JF; Guo QH; Cheng YB; Li Y; Wang JG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2024 Aug; 52(8):884-891. PubMed ID: 39143779
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevalence, phenotypic characteristics and prognostic role of apparent treatment resistant hypertension in the German Chronic Kidney Disease (GCKD) study.
    Mielke J; Trucks-Jansen H; Schurmann C; Kotsis F; Köttgen A; Schneider MP; Eckardt KU; ; Freitag DF; Eitner F; Becker MS
    J Hum Hypertens; 2023 May; 37(5):345-353. PubMed ID: 35534618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Office Blood Pressure Range and Cardiovascular Events in Patients With Hypertension: A Nationwide Cohort Study in South Korea.
    Kwon CH; Kim W; Shin JH; Lee CJ; Kim HC; Kang SH; Jung MH; Kim DH; Lee JH; Kim HL; Kim HM; Cho IJ; Cho I; Kang DR; Lee HY; Chung WJ; Ihm SH; Kim KI; Cho EJ; Sohn IS; Park S; Shin J; Ryu SK; Kang SM; Cho MC; Kim JH; Lee JH; Kim JY; Pyun WB; Sung KC
    J Am Heart Assoc; 2021 Apr; 10(7):e017890. PubMed ID: 33739126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.